Last reviewed · How we verify
lopinavir with ritonavir in 1:1 ratio
lopinavir with ritonavir in 1:1 ratio is a HIV protease inhibitor Small molecule drug developed by Drugs for Neglected Diseases. It is currently FDA-approved for HIV-1 infection in treatment-naïve and treatment-experienced patients, COVID-19 (investigational use in some regions during pandemic). Also known as: Lopinavir/ritonavir, Ritonavir.
Lopinavir and ritonavir are HIV protease inhibitors that block the viral protease enzyme, preventing the maturation of HIV particles and reducing viral replication.
Lopinavir and ritonavir are HIV protease inhibitors that block the viral protease enzyme, preventing the maturation of HIV particles and reducing viral replication. Used for HIV-1 infection in treatment-naïve and treatment-experienced patients, COVID-19 (investigational use in some regions during pandemic).
At a glance
| Generic name | lopinavir with ritonavir in 1:1 ratio |
|---|---|
| Also known as | Lopinavir/ritonavir, Ritonavir |
| Sponsor | Drugs for Neglected Diseases |
| Drug class | HIV protease inhibitor |
| Target | HIV protease |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Lopinavir inhibits HIV protease, an enzyme essential for cleaving viral polyproteins into functional components needed for infectious particle assembly. Ritonavir is a potent protease inhibitor that also acts as a pharmacokinetic booster, inhibiting cytochrome P450 metabolism and significantly increasing lopinavir plasma concentrations. Together in a 1:1 ratio, they provide enhanced and sustained antiretroviral activity against HIV.
Approved indications
- HIV-1 infection in treatment-naïve and treatment-experienced patients
- COVID-19 (investigational use in some regions during pandemic)
Common side effects
- Diarrhea
- Nausea
- Abdominal pain
- Headache
- Lipid elevation (hypertriglyceridemia, hypercholesterolemia)
- Hepatotoxicity
- Pancreatitis
Key clinical trials
- COVID-19 Study at the Russian Clinical and Research Center of Gerontology of the Pirogov RNRMU
- Pharmacokinetics of Lopinavir/Ritonavir Superboosting in Infants and Young Children Co-infected With HIV and TB (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- lopinavir with ritonavir in 1:1 ratio CI brief — competitive landscape report
- lopinavir with ritonavir in 1:1 ratio updates RSS · CI watch RSS
- Drugs for Neglected Diseases portfolio CI
Frequently asked questions about lopinavir with ritonavir in 1:1 ratio
What is lopinavir with ritonavir in 1:1 ratio?
How does lopinavir with ritonavir in 1:1 ratio work?
What is lopinavir with ritonavir in 1:1 ratio used for?
Who makes lopinavir with ritonavir in 1:1 ratio?
Is lopinavir with ritonavir in 1:1 ratio also known as anything else?
What drug class is lopinavir with ritonavir in 1:1 ratio in?
What development phase is lopinavir with ritonavir in 1:1 ratio in?
What are the side effects of lopinavir with ritonavir in 1:1 ratio?
What does lopinavir with ritonavir in 1:1 ratio target?
Related
- Drug class: All HIV protease inhibitor drugs
- Target: All drugs targeting HIV protease
- Manufacturer: Drugs for Neglected Diseases — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for HIV-1 infection in treatment-naïve and treatment-experienced patients
- Indication: Drugs for COVID-19 (investigational use in some regions during pandemic)
- Also known as: Lopinavir/ritonavir, Ritonavir
- Compare: lopinavir with ritonavir in 1:1 ratio vs similar drugs
- Pricing: lopinavir with ritonavir in 1:1 ratio cost, discount & access